GVK Biosciences and Endo Pharmaceuticals have entered into a collaboration agreement focused on discovering novel small molecules targeting a protein. GVK BIO will use its discovery expertise to deliver a clinical candidate and Endo will develop and commercialize the product arising out of this collaboration. This collaboration arose out of a newly launched concept at GVK BIO named Early Discovery Assets (EDA).
Manni Kantipudi, chief executive officer of GVK BIO, commented, “We are delighted to partner with Endo as it continues to build its discovery pipeline through external collaborations. This collaboration also confirms the value of our differentiated EDA concept, conceived to collaborate with pharmaceutical partners on discovery projects, from target to clinical candidates.”
Dr. Sandeep Gupta, Endo’s senior vice president of Drug Discovery and Early Development, remarked, “We are pleased to initiate this discovery collaboration with GVK BIO. With their world-class infrastructure and an experienced scientific team, I have no doubt that they will execute on the program goals and add to our portfolio of development candidates that provide novel treatment options for the patients”.
EDA is new discovery offering from GVK BIO, using its internal expertise in computational chemistry, discovery biology and medicinal chemistry to build a portfolio of discovery project assets for potential early stage partnering.